NEW YORK, November 27, 2017 /PRNewswire/ --
In keeping with the commitment to dynamically provide members
with timely information WallStEquities.com has issued free tailored
Stock Review on EW, GMED, IVC, and MDT which is a click away at
www.wallstequities.com/registration. WallStEquities.com has issued
research reports on Edwards Lifesciences Corp. (NYSE: EW), Globus
Medical Inc. (NYSE: GMED), Invacare Corp. (NYSE: IVC), and
Medtronic PLC (NYSE: MDT). Firms in the Medical Appliances and
Equipment industry primarily offer equipment and devices, which are
designed for diagnosis, monitoring, and treating patients in
healthcare systems worldwide. Wall St. Equities explores the latest
technical developments on today's equity selection at:
www.wallstequities.com/registration
Edwards Lifesciences
California headquartered
Edwards Lifesciences Corp.'s stock finished last Friday's session
0.49% higher at $109.34. A total
volume of 389,570 shares was traded. The Company's shares have
advanced 5.82% in the past month and 16.69% since the start of this
year. The stock is trading above its 50-day and 200-day moving
averages by 1.07% and 1.58%, respectively. Additionally, shares of
Edwards Lifesciences, which provides products and technologies to
treat structural heart disease and critically ill patients
worldwide, have a Relative Strength Index (RSI) of 60.37.
On October 31st, 2017
at the 29th Transcatheter Cardiovascular Therapeutics
in Denver, Edwards Lifesciences announced new data
demonstrating substantial economic advantages of the Edwards SAPIEN
3 transcatheter aortic heart valve for patients suffering from
severe, symptomatic aortic stenosis, who are at intermediate risk
for open-heart surgery. The analysis showed significantly lower
total one-year costs, on average, with the SAPIEN 3 valve compared
with surgical aortic valve replacement ($80,977 versus $96,489). Complimentary
subscription to our free research report on EW at:
www.wallstequities.com/registration/?symbol=EW
Globus Medical
On Friday, shares in Pennsylvania headquartered Globus Medical Inc.
ended the session 0.46% lower at $37.08. The stock recorded a trading volume of
194,217 shares. The Company's shares have gained 18.73% in the last
one month, 27.20% in the previous three months, and 49.46% on an
YTD basis. The stock is trading 17.39% above its 50-day moving
average and 20.76% above its 200-day moving average. Moreover,
shares of Globus Medicalhave an RSI of 70.53.
On November 10th, 2017,
research firm Bank of America/ Merrill upgraded the Company's stock
rating from 'Underperform' to 'Neutral'.
On November 20th, 2017,
Globus Medical announced that management plans to participate in
the Piper Jaffray 29th Annual Healthcare Conference on
November 29th, 2017, at
10:00 a.m. ET at the Lotte New York
Palace in New York City. An audio
webcast of the presentation will be available under the Investor
Relations page of the Company's website. Access the free research
report on GMED now by signing up at:
www.wallstequities.com/registration/?symbol=GMED
Invacare
Ohio headquartered Invacare
Corp.'s shares gained 0.28%, closing the session at $17.90 with a total trading volume of 107,884
shares. The stock has gained 17.38% in the last one month, 35.61%
over the previous three months, and 37.16% on an YTD basis. Shares
of the Company are trading 14.39% and 30.17% above their 50-day and
200-day moving averages, respectively. Additionally, shares of
Invacare, which together with its subsidiaries, designs,
manufactures, distributes, and exports medical equipment for use in
home health care, retail, and extended care markets worldwide, have
an RSI of 66.33.
On November 16th, 2017,
Invacare's Board of Directors declared a cash dividend of
$.0125 per share on the Company's
common shares and $.011364 per share
on its Class B common shares, payable on January 16th, 2018, to shareholders of
record on January 04th,
2018. Are you already registered with Wall St. Equities? Do so now
for free, and get the report on IVC at:
www.wallstequities.com/registration/?symbol=IVC
Medtronic
Last Friday at the close, shares in Ireland headquartered Medtronic PLC recorded a
trading volume of 3.17 million shares. The stock ended the session
1.11% higher at $83.25. The Company's
shares have advanced 5.11% in the past month, 5.30% over the
previous three months, and 16.87% since the start of this year. The
stock is trading above its 50-day and 200-day moving averages by
5.11% and 1.22%, respectively. Furthermore, shares of Medtronic
have an RSI of 66.24.
On November 20th, 2017,
Medtronic announced the US FDA approval and US commercial launch
for the Company's portfolio of AzureTM pacemakers with
BlueSyncTM technology. Available in both single chamber
and dual chamber models, the Azure XT MRI and Azure S MRI
pacemakers offer improved longevity, estimated at 13.7 years (dual
chamber) or 27% longer than its predecessor, so patients
likely need fewer device replacements. The new pacemakers also
allow patients to have MRI (magnetic resonance imaging) scans in
either 1.5 or 3 Tesla machines.
On November 22nd, 2017,
research firm Stifel reiterated its 'Hold' rating on the Company's
stock with an increase of the target price from $83 a share to $85
a share. Aspiring Member, please take a moment to register below
for your free research report on MDT at:
www.wallstequities.com/registration/?symbol=MDT
--
Wall St. Equities:
Wall St. Equities (WSE) produces regular sponsored and
non-sponsored reports, articles, stock market blogs, and popular
investment newsletters covering equities listed on NYSE and NASDAQ
and micro-cap stocks. WSE has two distinct and independent
departments. One department produces non-sponsored analyst
certified content generally in the form of press releases, articles
and reports covering equities listed on NYSE and NASDAQ and the
other produces sponsored content (in most cases not reviewed by a
registered analyst), which typically consists of compensated
investment newsletters, articles and reports covering listed stocks
and micro-caps. Such sponsored content is outside the scope of
procedures detailed below.
WSE has not been compensated; directly or indirectly; for
producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by
a writer (the "Author") and is fact checked and reviewed by a
third-party research service company (the "Reviewer") represented
by a credentialed financial analyst [for further information on
analyst credentials, please email info@wallstequities.com.
Rohit Tuli, a CFA® charterholder
(the "Sponsor"), provides necessary guidance in preparing the
document templates. The Reviewer has reviewed and revised the
content, as necessary, based on publicly available information
which is believed to be reliable. Content is researched, written
and reviewed on a reasonable-effort basis. The Reviewer has not
performed any independent investigations or forensic audits to
validate the information herein. The Reviewer has only
independently reviewed the information provided by the Author
according to the procedures outlined by WSE. WSE is not entitled to
veto or interfere in the application of such procedures by the
third-party research service company to the articles, documents or
reports, as the case may be. Unless otherwise noted, any content
outside of this document has no association with the Author or the
Reviewer in any way.
NO WARRANTY
WSE, the Author, and the Reviewer are not responsible for any
error which may be occasioned at the time of printing of this
document or any error, mistake or shortcoming. No liability is
accepted whatsoever for any direct, indirect or consequential loss
arising from the use of this document. WSE, the Author, and the
Reviewer expressly disclaim any fiduciary responsibility or
liability for any consequences, financial or otherwise arising from
any reliance placed on the information in this document.
Additionally, WSE, the Author, and the Reviewer do not (1)
guarantee the accuracy, timeliness, completeness or correct
sequencing of the information, or (2) warrant any results from use
of the information. The included information is subject to change
without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or
a solicitation of an offer to buy or sell the securities mentioned
or discussed, and is to be used for informational purposes only.
Please read all associated disclosures and disclaimers in full
before investing. Neither WSE nor any party affiliated with us is a
registered investment adviser or broker-dealer with any agency or
in any jurisdiction whatsoever. To download our report(s), read our
disclosures, or for more information, visit
https://wallstequities.com/legal-disclaimer/
CONTACT
For any questions, inquiries, or comments reach out to us directly.
If you're a company, we are
covering and wish to no longer feature on our coverage list contact
us via email and/or phone between 09:30 EDT
to 16:00 EDT from Monday to Friday at:
Email: info@wallstequities.com
Phone number: +21-32-044-483
Office Address: 1 Scotts Road #24-10, Shaw Center Singapore
228
CFA® and Chartered Financial Analyst® are registered trademarks
owned by CFA Institute.
SOURCE Wall St. Equities